Oculis Holding AG (OCS) Current Assets (2021 - 2026)
Oculis Holding AG's (OCS) quarterly Current Assets came in at $289.9 million in Q1 2026, up 38.07% year-on-year from $210.0 million in Q1 2025, and up 5.86% quarter-over-quarter from $273.9 million in Q4 2025.
Oculis Holding AG (OCS) Current Assets (2021 - 2026) Analysis & Trends
Oculis Holding AG's Current Assets history runs 6 years deep, the most recent figure standing at $289.9 million for Q1 2026.
- On a quarterly basis, Current Assets rose 38.07% year-over-year to $289.9 million in Q1 2026; TTM through Mar 2026 was $289.9 million, a 38.07% increase from a year earlier, with the FY2025 full-year figure at $264.0 million, up 121.42% from the prior year.
- Current Assets climbed to $289.9 million in Q1 2026 per OCS's latest filing, from $273.9 million in the prior quarter.
- Across five years, Current Assets topped out at $289.9 million in Q1 2026 and bottomed at $24.6 million in Q4 2022.
- The 5-year median for Current Assets is $135.0 million (2023), against an average of $157.8 million.
- Across the five-year window, Current Assets tumbled 52.81% in 2022 and jumped 363.75% in 2023, its largest moves.
- Year by year, Current Assets stood at $24.6 million in 2022, then jumped by 363.75% to $113.9 million in 2023, then rose by 5.15% to $119.7 million in 2024, then jumped by 128.71% to $273.9 million in 2025, then gained by 5.86% to $289.9 million in 2026.
- Per Business Quant, the three latest OCS Current Assets figures stand at $289.9 million (Q1 2026), $273.9 million (Q4 2025), and $188.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 289.93 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 73.04 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.59 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 6.60 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 11.73 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 18.21 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 521.86 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.97 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 4.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 289.93 Mn |
| Dec 31, 2025 | 273.87 Mn |
| Sep 30, 2025 | 188.65 Mn |
| Jun 30, 2025 | 200.75 Mn |
| Mar 31, 2025 | 209.98 Mn |
| Dec 31, 2024 | 119.74 Mn |
| Sep 30, 2024 | 128.68 Mn |
| Jun 30, 2024 | 137.82 Mn |
| Mar 31, 2024 | 97.89 Mn |
| Dec 31, 2023 | 113.88 Mn |
| Sep 30, 2023 | 130.76 Mn |
| Jun 30, 2023 | 134.98 Mn |
| Dec 31, 2022 | 24.56 Mn |
| Dec 31, 2021 | 52.04 Mn |